View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Thibault Leneeuw
  • Thomas Couvreur
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adyen: CMD press release; strong growth for the years ahead. Heijmans: Nice bolt-on! Kendrion: Hitting a 15.5% EBITDA margin in 3Q25. Staffing Sector: French staffing: September trend weaker but October outlook slightly better despite tougher comps. TKH Group: Weak 3Q EBITA, keeps FY outlook

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...

Martijn Den Drijver
  • Martijn Den Drijver

TKH GROUP NV : Massive value creation in the works…if executed well

We upgrade TKH from Neutral to Outperform with a DCF/SOTP based price target of €48 per share. TKH has decided to divest Electrification (EF), Digitization and other non-core units, with the largest divestments expected in the next 6 to 18 months. We estimate the proceeds to be c. € 640m, of which the vast majority will be returned to shareholders via share buy backs. Together with regular dividend of the core activities, this implies a cash return (on average) in the next three years of € 7 per...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aedifica: €21m investment in the development of 3 care homes in Finland. CTP: Highlights from 2-day CMD in Germany. dsm-firmenich: Softly does it. Prosus: Expanding the ecosystem. Randstad: Preliminary preview 3Q25F results due 22 October. TKH Group: Change is coming. UCB: Renewed tariff threat on US branded pharma unlikely to affect UCB

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch